Ningbo Tianyi Medical Instrument Co., Ltd
Initial public offering and listing on GEM
Suggestive announcement of listing announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
With the approval of Shenzhen Stock Exchange, the RMB ordinary shares issued by Ningbo Tianyi Medical Devices Co., Ltd. (hereinafter referred to as “the company” or “the company”) will be listed on the gem of Shenzhen Stock Exchange on April 7, 2022, The full text of the listing announcement and the full text of the prospectus for initial public offering and listing on the gem are disclosed on the information disclosure website designated by the China Securities Regulatory Commission (www.cn. Info. Com. CN) China Securities Network (www.cs. Com. CN.) China Securities Network (www.cn. Stock. Com.) Securities Times (www.stcn. Com.) Securities Daily (www.zqrb. CN.), For investors to consult. QR code of web page: cninfo.com I. listing overview
1. Stock abbreviation: Tianyi medical
2. Stock Code: 301097
3. Total share capital after IPO: 58947368 shares
4. Increased shares in initial public offering: 14736842 shares. This public offering is all new shares without transfer of old shares. II. Risk warning
The company’s shares will be listed on the growth enterprise market of Shenzhen Stock Exchange, which has high investment risk. GEM companies have the characteristics of unstable performance, high operation risk and high delisting risk, and investors are facing greater market risk. Investors should fully understand the investment risks of the gem and the risk factors disclosed by the company, and make investment decisions prudently.
According to the industry classification guidelines of listed companies (revised in 2012) issued by the China Securities Regulatory Commission, the industry of the issuer is special equipment manufacturing (C35). As of March 18, 2022 (T-3), the static average p / E ratio of the industry in the latest month released by China Securities Index Co., Ltd. was 36.39 times. The offering price of 52.37 yuan / share corresponds to the issuer’s net profit diluted P / E ratio of 60.08 times before and after deducting non recurring profits and losses in 2020, which is higher than the industry’s average static P / E ratio in the latest month released by China Securities Index Co., Ltd. on March 18 (T-3), 2022, with an excess range of 65.10%. The rationality of the offering price is explained as follows: first, Leading industry position and brand influence: the company is one of the earliest enterprises engaged in medical consumables in the field of blood purification and ward nursing in China. The company has a certain brand influence in the field of blood purification consumables, and its product sales cover 31 provinces, municipalities and autonomous regions in China; In the international market, the final sales of the company’s products cover countries and regions such as Asia, Europe, North America, South America and Africa. The company has maintained stable and growing business cooperation with international giants in the industries such as Fresenius Medical, Baxter medical, Medtronic and niplow for many years. According to the product sales ranking, the company ranked second in the market share of cardiopulmonary bypass in China in 2019, and has strong competition among comparable companies in the same industry in the Chinese market; Meanwhile, the proportion of overseas sales of the company increased from 6.10% in 2018 to 41.69% from January to June 2021, and the proportion of overseas sales increased rapidly. In addition, as one of the drafting units, the company participated in the formulation of the national industrial standards extracorporeal circulation blood circuit of cardiovascular implants and artificial organ blood purification devices (yy02672008) and extracorporeal circulation blood circuit of hemodialysis and related therapeutic blood purification devices (yy02672016). Wu Zhimin, chairman and general manager of the company, served as one of the main drafters of these two standards. Second, fruitful R & D achievements: the company attaches great importance to the accumulation and investment of technological R & D, adheres to technological innovation and continuously increases the investment in technological R & D. The company has 28 patents, including 8 invention patents, 17 utility model patents and 3 design patents. Third, rich product pipelines: the company provides many kinds of polymer medical devices in the fields of blood purification and ward nursing. At present, the products produced and sold by the company are mainly: extracorporeal circulation blood circuit, disposable arteriovenous puncture device, liquid feeding tube and feeder, and disposable integrated oxygen suction tube. Among them, the company’s cardiopulmonary bypass blood products have 114 specifications and models, which meet the diversified clinical needs of different treatment modes, clinical use habits and machine adaptability. The basic type and CRRT special type cover the treatment methods such as hemodialysis and CRRT, and play an important role in the market competition. Fourth, strong net profit growth rate: the net profits attributable to the shareholders of the parent company in 2018, 2019, 2020 and January June 2021 were 445779 million yuan, 632038 million yuan, 871495 million yuan and 26.727 million yuan respectively, with an average annual compound growth rate of 39.82% from 2018 to 2020. Fifth, perfect quality assurance system and international recognition of product quality: the company has passed eniso134852016 quality management system certification and obtained 24 Chinese medical device registration / filing certificates, including 17 class II medical device registration certificates and 7 class III medical device registration certificates. In addition, the company has passed the FDA enterprise filing, and some products have passed the EU CE certification and FDA product listing, indicating that the company’s product quality control system complies with international standards and has been recognized by authoritative institutions and enterprises in the industry.
As of March 18, 2022 (T-3), the valuation levels of comparable listed companies are as follows:
The static securities code corresponding to the T-3 day shares in 2020. The securities are simply deducted before and after the deduction. The closing price state p / E ratio state p / E ratio is called EPS (before and after RMB EPS (yuan / (deducting non (deducting non / share) / share))
Jiangxi Sanxin Medtec Co.Ltd(300453) .SZ Jiangxi Sanxin Medtec Co.Ltd(300453) 0.2934 0.2565 10.95 37.32 42.70
Well Lead Medical Co.Ltd(603309) .SH Well Lead Medical Co.Ltd(603309) 0.5218 0.5241 14.69 28.15 28.03
Shanghai Kindly Enterprises Development Group Co.Ltd(603987) .SH Shanghai Kindly Enterprises Development Group Co.Ltd(603987) 0.4592 0.4187 20.68 45.03 49.40
Mean value — 36.83 40.04
Data source: wind information, data as of March 18, 2022 (T-3).
Note: non recurring profit before / after 20232023 (excluding EPS) of the parent company.
2. Tiankang medical (835942. OC), a comparable company of the issuer, terminated the listing of its shares in the National SME share transfer system from August 31, 2020, and the calculation of the average static P / E ratio did not include Tiankang medical.
The issuance price of 52.37 yuan / share corresponds to the issuer’s net profit diluted P / E ratio of 60.08 times before and after deducting non recurring profits and losses in 2020, which is higher than the industry’s average static P / E ratio in the latest month released by China Securities Index Co., Ltd. on March 18 (T-3), 2022, with an excess range of 65.10%; It is 40.04 times higher than the average static P / E ratio of comparable companies after deducting non-profit in 2020, with an excess range of 50.05%. There is a risk that the decline of the issuer’s share price will bring losses to investors in the future.
There is a risk that the net asset scale will increase significantly due to the acquisition of raised funds, which will have an important impact on the issuer’s production and operation mode, operation management and risk control ability, financial status, profitability and long-term interests of shareholders. The issuer and the recommendation institution (lead underwriter) remind investors to pay attention to investment risks, carefully study and judge the rationality of issuance pricing, and make investment decisions rationally. 3、 Contact information
(I) contact information of the company company name: Ningbo Tianyi medical device Co., Ltd. legal representative: Wu Zhimin domicile: No. 788, Mozhi North Road, Dongqianhu tourist resort, Ningbo Tel: 057455011010 contact person: Zhang Chongliang (II) contact information of the sponsor and the sponsor representative sponsor (lead underwriter): Guotai Junan Securities Co.Ltd(601211) legal representative: He Qing domicile: China (Shanghai) 618 Shangcheng Road, pilot Free Trade Zone Tel: 02138676666 sponsor representatives: Shen Yichong, Shui Yaodong
(there is no text on this page, which is the seal page of the suggestive announcement of the listing announcement of Ningbo Tianyi medical device Co., Ltd. on its initial public offering and listing on the GEM)
Ningbo Yitian Medical Instrument Co., Ltd
(there is no text on this page, which is the seal page of the suggestive announcement of the listing announcement of Ningbo Tianyi medical device Co., Ltd. on its initial public offering and listing on the GEM)
Guotai Junan Securities Co.Ltd(601211) mm / DD / yyyy
